JP2020536892A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536892A5
JP2020536892A5 JP2020520112A JP2020520112A JP2020536892A5 JP 2020536892 A5 JP2020536892 A5 JP 2020536892A5 JP 2020520112 A JP2020520112 A JP 2020520112A JP 2020520112 A JP2020520112 A JP 2020520112A JP 2020536892 A5 JP2020536892 A5 JP 2020536892A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
activator
composition according
hours
paddle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020520112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/054830 external-priority patent/WO2019074829A1/en
Publication of JP2020536892A publication Critical patent/JP2020536892A/ja
Publication of JP2020536892A5 publication Critical patent/JP2020536892A5/ja
Priority to JP2023090883A priority Critical patent/JP2023123471A/ja
Withdrawn legal-status Critical Current

Links

JP2020520112A 2017-10-09 2018-10-08 医薬レジネート組成物、それを作製する方法、およびその使用 Withdrawn JP2020536892A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023090883A JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569813P 2017-10-09 2017-10-09
US62/569,813 2017-10-09
PCT/US2018/054830 WO2019074829A1 (en) 2017-10-09 2018-10-08 RESINATE-BASED PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090883A Division JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Publications (2)

Publication Number Publication Date
JP2020536892A JP2020536892A (ja) 2020-12-17
JP2020536892A5 true JP2020536892A5 (enExample) 2021-11-18

Family

ID=66100936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520112A Withdrawn JP2020536892A (ja) 2017-10-09 2018-10-08 医薬レジネート組成物、それを作製する方法、およびその使用
JP2023090883A Pending JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023090883A Pending JP2023123471A (ja) 2017-10-09 2023-06-01 医薬レジネート組成物、それを作製する方法、およびその使用

Country Status (9)

Country Link
US (3) US11690840B2 (enExample)
EP (1) EP3694555A4 (enExample)
JP (2) JP2020536892A (enExample)
KR (1) KR102901919B1 (enExample)
CN (2) CN119524126A (enExample)
AU (3) AU2018347991A1 (enExample)
CA (1) CA3078844A1 (enExample)
IL (2) IL311303B2 (enExample)
WO (1) WO2019074829A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102881925B1 (ko) * 2022-02-22 2025-11-06 인제대학교 산학협력단 양이온교환수지를 사용한 약물의 방출 조절을 위한 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544761A (en) 1976-11-26 1979-04-25 Pennwalt Corp Prolonged release pharmaceutical preparations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
MXPA02000725A (es) * 1999-07-29 2003-07-14 Roxane Lab Inc Formulacion opioide de liberacion sostenida.
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AR039744A1 (es) 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US8343546B2 (en) 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
WO2008151071A1 (en) 2007-05-30 2008-12-11 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
JP5482012B2 (ja) * 2008-09-19 2014-04-23 セイコーエプソン株式会社 ターゲット支持装置、ターゲット搬送機構及び液体噴射装置
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
US8623409B1 (en) * 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
KR20130124551A (ko) * 2011-02-02 2013-11-14 알파마 파머슈티컬스 엘엘씨 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
EP2726065A4 (en) 2011-06-30 2014-11-26 Neos Therapeutics Lp MISS-BROKEN MEDICINAL PRODUCTS
WO2013119231A1 (en) 2012-02-09 2013-08-15 Tris Pharma, Inc. Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings
TW201722406A (zh) 2012-03-02 2017-07-01 羅德製藥公司 抗破壞性立即釋出型調製劑類
WO2014159340A1 (en) * 2013-03-13 2014-10-02 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
MA41152A (fr) 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
CA3039920A1 (en) * 2016-10-10 2018-04-19 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof

Similar Documents

Publication Publication Date Title
US8987291B2 (en) Opioid-containing oral pharmaceutical compositions and methods
JP2015044834A5 (enExample)
AU2011271429B2 (en) Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
RU2004106619A (ru) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
RU2000101024A (ru) Опоидные анальгетики с контролируемым высвобождением активных веществ
JP2005247859A5 (enExample)
JP2015511953A5 (enExample)
JP2014510094A5 (enExample)
HRP20120641T1 (hr) Oralni farmaceutski oblici doziranja otporni na neovlašteno korištenje koji sadrže opioidni analgetik
CA2547334A1 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
JP2011137020A5 (enExample)
HRP20150835T1 (hr) Farmaceutski oblici doziranja s kontroliranim oslobađanjem
JP2004515455A5 (enExample)
JP2015500273A5 (enExample)
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
JP2010511683A5 (enExample)
JP2016014040A5 (enExample)
ME00398B (me) Oralne formulacije opijatnog agonista otporne na mehaničke, termičke i/ili hemijske promjene fizičkih osobina doznog oblika
JP2011519930A5 (enExample)
WO2008045556A2 (en) Novel synergistic opioid-cannabinoid codrug for pain management
WO2020055725A4 (en) Dopamine d3 receptor selective antagonists/partial agonists and uses thereof
JP2018080197A (ja) オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
KR20190026003A (ko) 중수소화 덱스트로메토르판의 합성 방법
JP2017526719A5 (enExample)
JP2013510842A5 (enExample)